Position in KYMR
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$28,667,500
-$33,800,000 QoQ
Shares Held
250,000
-66.7% QoQ
Ownership
0.301%
of shares outstanding
% of Portfolio
1.72%
of 13F equity value
Holder Rank
#47
of 273 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KYMR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Commodore Capital LP holds $1,375,688,495 across 28 Biotechnology names. KYMR ranks #16 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RLAY |
Relay Therapeutics, Inc.
|
12,000,000 | $224,520,000 | |
| 2 | ELVN |
Enliven Therapeutics, Inc.
|
3,275,000 | $166,206,250 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
3,050,000 | $118,035,000 | |
| 4 | DFTX |
Definium Therapeutics, Inc.
|
2,000,000 | $94,080,000 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
|
846,786 | $75,177,661 | |
| 6 | ANRO |
Alto Neuroscience, Inc.
|
2,723,196 | $71,865,142 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
2,250,000 | $70,335,000 | |
| 8 | EYPT |
EyePoint, Inc.
|
4,600,000 | $65,780,000 |
All Filings in KYMR
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $28,667,500 | 250,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $62,467,500 | 750,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $58,357,500 | 750,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $42,450,000 | 750,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $32,730,000 | 750,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||